Therapeutic effects of alpha lipoic acid and/or caffeine-loaded chitosan nanoparticles on memory impairment and neurochemical changes in high-fat diet-induced obese rats
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Alpha lipoic acid (LA) or caffeine-loaded chitosan nanoparticles (CCNPs) can treat memory loss caused by obesity. These treatments improved cognitive function and reduced obesity markers in rats, showing potential for managing obesity-related cognitive decline.
Area Of Science
- Neuroscience
- Pharmacology
- Biochemistry
Background
- Obesity is linked to cognitive deficits, including memory impairment.
- High-fat diets induce neurochemical and histopathological changes in the brain.
- Understanding the mechanisms behind obesity-induced memory dysfunction is crucial for developing effective therapies.
Purpose Of The Study
- To evaluate the therapeutic effects of alpha lipoic acid (LA) and/or caffeine-loaded chitosan nanoparticles (CCNPs) on obesity-induced memory impairment in rats.
- To investigate the impact of LA and/or CCNPs on neurochemical, oxidative stress, and inflammatory markers in the brain.
- To assess the potential of LA and/or CCNPs as therapeutic agents for obesity-related cognitive dysfunction.
Main Methods
- Rats were induced into obesity using a high-fat diet (HFD).
- Obese rats were treated with LA and/or CCNPs.
- Memory and cognitive functions were assessed using the novel object recognition test (NORT).
- Neurochemical analyses (neurotransmitters, oxidative stress markers, inflammatory cytokines) and histopathological examinations were performed on brain tissues.
Main Results
- Obese rats exhibited impaired memory, increased body mass index (BMI), and significant alterations in brain neurochemistry and structure.
- Treatment with LA and/or CCNPs reduced BMI, improved memory performance, and alleviated neurochemical and histopathological changes.
- Both LA and CCNPs demonstrated antioxidant and anti-inflammatory properties.
- No synergistic effect was observed between LA and CCNPs.
Conclusions
- LA or CCNPs show promise as potential therapies for obesity-induced memory impairment.
- These agents may exert their effects by restoring monoamine levels and reducing oxidative stress and inflammation.
- Further research is warranted to explore the clinical applicability of LA and CCNPs in managing obesity-related cognitive decline.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...